Table 2

 Changes in individual measures of the ACR response

ACR criteria [mean (SD)]Leflunomide + sulfasalazine (n = 56)Placebo + sulfasalazine (n = 50)
Baseline (week 24)End point (week 48)Change from baselineBaseline (week 24)End point (week 48)Change from baselinep Value*
*One sided p value; placebo + sulfasalazine versus leflunomide + sulfasalazine; †the functional disability index is based on the sum of the highest scores for each category, divided by the number of categories scored; ‡the HAQ score represents sum of the mean scores for each category, divided by the number of categories.
SD, standard deviation; TJC, tender joint count; SJC, swollen joint count; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; HAQ, Health Assessment Questionnaire.
TJC12.36 (7.35)9.68 (8.20)−2.68 (6.37)13.92 (7.20)12.52 (8.45)−1.40 (6.93)0.09
SJC9.84 (6.94)8.34 (6.86)−1.50 (4.84)10.82 (6.02)10.06 (7.36)−0.76 (5.72)0.39
ESR (mm/1st h)43.20 (24.91)38.32 (25.53)−4.88 (25.65)41.54 (25.03)36.12 (24.93)−5.42 (21.50)0.38
CRP (mg/l)24.15 (28.00)19.05 (20.93)−4.87 (26.60)22.60 (25.68)25.88 (31.40)+3.28 (28.31)0.40
Pain intensity assessment (mm)50.27 (23.69)41.05 (26.85)−9.21 (24.91)49.92 (22.09)41.60 (24.41)−8.32 (21.74)0.4292
Functional disability index†1.29 (0.69)1.18 (0.72)−0.11 (0.38)1.39 (0.64)1.36 (0.65)−0.03 (0.39)
HAQ score‡1.08 (0.63)0.99 (0.65)−0.09 (0.32)1.16 (0.60)1.14 (0.61)−0.02 (0.36)